1   The rate of hypoglycemia was 12% less with insulin lispro (6.4 +/- 0.2 vs. 7.2 +/- 0.3 episodes/30

2                                              Insulin lispro, an insulin analog recently developed par

3                                  We compared insulin lispro and regular human insulin in the mealtime

4      Our studies employed Lys(B28), Pro(B29)-insulin ("lispro") as a model prandial analog that is le

5                   No evidence was noted that insulin lispro differs in immunogenicity from RHI in pre

6                               In conclusion, insulin lispro improves postprandial control, reduces hy

7 nsulin glargine, both combined with prandial insulin lispro, in patients with type 2 diabetes.

8       Used as prandial insulin (for example, insulin lispro, insulin aspart, or insulin glulisine) an

9  comparators (glimepiride, insulin glargine, insulin lispro, liraglutide, pioglitazone, or sitaglipti

10                                              Insulin lispro [Lys (B28), Pro (B29) human insulin] is a

11                       For patients receiving insulin lispro, no significant changes occurred in antib

12 en with glargine once daily and rapid-acting insulin lispro or aspart before meals (the basal-bolus g

13  of patients were randomly assigned to begin insulin lispro or continue on RHI.

14 t 2 h by 2.0 mmol/l in patients treated with insulin lispro (P < 0.001).

15 esence of insulin-specific antibodies (ISA), insulin lispro-specific antibodies (LSA), and cross-reac

16 umber of hypoglycemic episodes was less with insulin lispro than with regular human insulin therapy d

17 serum glucose was significantly lower during insulin lispro therapy.

18  trials, we contrasted the immunogenicity of insulin lispro versus regular human insulin (RHI) in pat

19                                              Insulin lispro was injected immediately before the meal,